Table 1 Summary of the research phase of the mTOR inhibitors
From: mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
mTOR inhibitors | Applied tumor | Phase | References |
|---|---|---|---|
Everolimus | RCC | FDA approved | – |
Temsirolimus | Advanced RCC | FDA approved | – |
ICSN3250 | Colon cancer cell | Pre-clinical studies | Nguyen et al. [53] |
LY3023414 | Solid tumor or lymphoma | Phase I clinical trial | Bendell et al. [54] |
OSU-53 | Thyroid cancer cell | Pre-clinical studies | Plews et al. [55] |
AZD8055 | OCCC cell | Pre-clinical studies | Caumanns et al. [59] |
Everolimus | Aggressive and RAIR thyroid cancer | Phase II clinical trial | Hanna et al. [60] |
Rapamycin | Pancreatic cancer | Pre-clinical studies | Morran et al. [61] |
Temsirolimus | PCNSL | Phase II clinical trial | Korfel et al. [62] |